$GILD double bottom set upGilead Sciences, Inc.BATS:GILDSmiertSpionam GILD Fundamental Analysis Gilead Sciences has demonstrated resilient core performance driven by its HIV and antiviral franchises, with Q1 2026 revenue of approximately $6.96 billion, up about 4 % year-over-year, and net income expanding over 50 % versus the prior year on EPS of $1.61 (diluted) – outperforming consensus expectations. The company also raised full-year 2026 product sales guidance to about $30–30.4 billion, supported by strong demand for its HIV portfolio and growth in key therapies such as Biktarvy and Descovy. However, earnings guidance was revised lower due to substantial acquisition-related charges, which are expected to pressure profitability in the near term. Overall, fundamentals reflect solid revenue growth and profitability metrics, supported by product leadership and an attractive dividend yield, balanced against transitional cost headwinds and integration risk. Technical Analysis Technically, GILD has formed a double bottom pattern near key support levels, suggesting a potential base and bullish reversal structure on the daily chart. Price action is also respecting the 200 EMA as a strong support level, reinforcing the long-term uptrend and providing structural confirmation for a potential continuation higher. Trade Setup Based on this technical framework, an entry on bullish confirmation (e.g., breakout above the interim neckline of the double bottom) can be considered. Take-Profit 1 (TP1): Next defined resistance zone around recent swing highs/congestion levels. Risk Management A disciplined stop-loss/ hedge stop should be placed below the pattern’s support to manage downside risk, with position sizing aligned to broader portfolio risk tolerance. Note: This is a structured market observation and not personalised financial advice; always conduct your own due diligence.